US8989201038
© PR Newswire
09.12.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
News Preview
TAMPA, Fla., Dec. 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 9,462,423 shares of its com...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
News Preview
Oral Presentation highlighted new scientific evidence that DOR is expressed on tumor-associated Myeloid-Derived Suppressor Cells (MDSCs), and its inhibition decreases immune suppressing capabilities of MDSCs by downregulating expression of multiple genes associated with MDSC induced immunosuppression Data presented in the Company's poster demonstr...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
News Preview
Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway, conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA)...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
03.11.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
News Preview
Oral presentation highlights the first time it's been demonstrated that the DOR is expressed on tumor-associated MDSCs, and that DOR inhibition reprograms multiple mechanisms of MDSC- induced immunosuppression representing a new target in overcoming acquired resistance to cancer immunotherapy...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
20.08.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
News Preview
TAMPA, Fla., Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present at the 27th Annual H.C. Wainwright Global Investment Conference taking place September 8-10, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
14.08.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
News Preview
Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in relapsed/refractory NPM1-mutated Acute Myeloid Leukemia (AML) in combination with a menin inhibitor in 2H 2025
Initiated a Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy w...
Themefolio
Profiler
Peergroup
© PR Newswire
01.07.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
News Preview
TAMPA, Fla., July 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that the Company has been added to the Russell 3000® Index, with automatic inclusion in the Russell 2000® Inde...
Themefolio
Profiler
Peergroup
© PR Newswire
30.06.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences Completes Acquisition of Kineta
News Preview
Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline
TuHURA planning to initiate a Phase 2 randomized trial involving VISTA inhibiting antibody in 2nd Half 2025
Completion of the acquisition unlocks the fourth tranche of funds from $12.5 million aggregate PIPE financing an...
Themefolio
Profiler
Peergroup
© PR Newswire
24.06.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
News Preview
Phase 3 trial being conducted under a Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA)
Primary endpoint of Overall Response Rate (ORR) qualifies for accelerated approval process
Key secondary endpoint of Progression Free Survival (PFS) may satisfy the requirement for a post confirmatory trial, converting a...
Themefolio
Profiler
Peergroup
© PR Newswire
23.06.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
News Preview
TAMPA, Fla. and SEATTLE, June 23, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced with Kineta, Inc. (OTC Pink:KANT) ("Kineta"), a clinical-stage biotechnology company focused on t...
Themefolio
Profiler
Peergroup
© PR Newswire
09.06.2025
HURA
LISTED
NASDAQ
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
News Preview
Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as first-line treatment for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) Agreement with U.S. Food and Drug Administration (FDA), later in June 2025
Resolu...
Themefolio
Profiler
Peergroup
© PR Newswire
03.06.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy
News Preview
Secures $12.5 million of commitments in a private offering
Secures an additional $3.0 million through payment of cash exercise price of warrants
Funding provides capital for:
Initiation of planned Phase 3 accelerated approval trial of IFx-2.0 targeting 40% enrollment by 2-2025 year endAcquisition of and initiating a Phase 2 trial in NPM1 mutated...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
02.06.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
News Preview
Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda® (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC) detailed in Trial in Progress Poster at ASCO
Phase 3 trial of IFx-Hu2.0 to be conducted under Accelerated Approval Pathway and Special Protocol Assessment (SPA) agreem...
Themefolio
Profiler
Peergroup
© PR Newswire
15.05.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
News Preview
Anticipates initiating the Company's Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA), in Q2 2025
Initiated a...
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference
News Preview
TAMPA, Fla., May 13, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, will present a company overview, including highlig...
Themefolio
Profiler
Peergroup
© PR Newswire
05.05.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)
News Preview
Phase 1b/2a trial designed to evaluate the safety and feasibility of IFx-Hu2.0 in combination with Keytruda® when administered via Interventional Radiology (IR) in patients with deep- seated tumors without associated cutaneous tumors
TAMPA, Fla., May 5, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Pha...
Themefolio
Profiler
Peergroup
© PR Newswire
28.04.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meet
News Preview
Kineta presents updated clinical data from VISTA-101 trial of KVA12123, demonstrating >90% VISTA receptor occupancy at 1,000mg dose level throughout the trial's every two weekly dosing interval (Q2W)
TuHURA's Phase 3-ready IFx2.0 produced clinically meaningful anti-tumor responses and abscopal effect, after checkpoint inhibitor (CPI) therapy f...
Themefolio
Profiler
Peergroup
© PR Newswire
08.04.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting
News Preview
TAMPA, Fla., April 8, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that an abstract highlighting Kineta Inc.'s novel KVA12123 antibody and an abstract from Moffitt Cancer Center scientists exam...
Themefolio
Profiler
Peergroup
© PR Newswire
07.04.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
News Preview
Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical/clinical candidates and 7 investigational new drug / clinical trial applications
Extensive knowledge in the biochemistry and pharmacology of the Delta Opioid Receptor (DOR), the primary target in TuHURA's Antibody Drug Conjugate (ADC) and Antibody Pept...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
News Preview
Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC) planning to initiate enrollment in Q2 2025
MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA) Agreement with FDA
Acquisition of Kineta's Phase 2 ready, VISTA inhibiting...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.03.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors
News Preview
Dr. Tendler oversaw 30 Major Drug Approvals, including worldwide approvals for J&J's transformational treatments in hematologic malignancies, prostate, lung and bladder cancersDr. Tendler also oversaw 13 FDA Breakthrough Designations accelerating the early development of promising investigational medicines intended for treatment of serious onco...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
10.03.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
News Preview
Live webcast fireside chat on Tuesday, March 18th at 8:30 AM PT TAMPA, FL / ACCESS Newswire / March 10, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., Pre...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.02.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
News Preview
On-demand video webcast now available here TAMPA, FL / ACCESS Newswire / February 19, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced it participated in the Virtual Investor "Top...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
HURA
LISTED
NASDAQ
HURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of TuHURA Biosciences, Inc. Is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of TuHURA Biosciences, Inc. (NASDAQ: HURA) and Kineta, Inc. is fair to TuHURA shareholders.
Halper Sadeh encourages TuHURA shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.12.2024
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
News Preview
Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA's late stage pipelineTargeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025Cross product and technology synergies build on TuHURA's therapeutic focus on overcoming primary and acquired resistance to cancer immunotherapyProposed Transaction expected...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
25.11.2024
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
News Preview
IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line treatment of Merkel Cell Carcinoma (MCC) under Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA)Entered into a non-binding letter of intent with Kineta...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
23.10.2024
HURA
LISTED
NASDAQ
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
News Preview
TAMPA, FL / ACCESSWIRE / October 23, 2024 / TuHURA Biosciences, Inc. (Nasdaq:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that TuHURA recently participated at the 2024 Maxim Healthcare Virtual...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
22.10.2024
HURA
LISTED
NASDAQ
TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event
News Preview
Live moderated webcast with Dr. Jim Bianco, President and Chief Executive Officer of TuHURA on Wednesday, October 30th at 4 PM ET TAMPA, FL / ACCESSWIRE / October 22, 2024 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to ov...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
